Iterum Therapeutics (NASDAQ:ITRM) & Ensysce Biosciences (NASDAQ:ENSC) Head-To-Head Survey

Ensysce Biosciences (NASDAQ:ENSC) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, valuation, risk and dividends.

Risk & Volatility

Ensysce Biosciences has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, Iterum Therapeutics has a beta of 2.96, indicating that its share price is 196% more volatile than the S&P 500.

Institutional and Insider Ownership

5.6% of Ensysce Biosciences shares are owned by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are owned by institutional investors. 2.8% of Ensysce Biosciences shares are owned by insiders. Comparatively, 2.0% of Iterum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Ensysce Biosciences and Iterum Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ensysce Biosciences	-280.53%	-2,550.30%	-320.49%
Iterum Therapeutics	N/A	N/A	-65.54%

Earnings and Valuation

This table compares Ensysce Biosciences and Iterum Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ensysce Biosciences	$5.07 million	1.49	-$10.18 million	($2.76)	-0.14
Iterum Therapeutics	$390,000.00	4.10	-$24.77 million	($0.75)	-0.04

Ensysce Biosciences has higher revenue and earnings than Iterum Therapeutics. Ensysce Biosciences is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Ensysce Biosciences and Iterum Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ensysce Biosciences	1	0	2	0	2.33
Iterum Therapeutics	1	2	0	0	1.67

Ensysce Biosciences currently has a consensus target price of $2.00, indicating a potential upside of 416.53%. Given Ensysce Biosciences’ stronger consensus rating and higher probable upside, research analysts plainly believe Ensysce Biosciences is more favorable than Iterum Therapeutics.

Summary

Iterum Therapeutics beats Ensysce Biosciences on 8 of the 14 factors compared between the two stocks.

About Ensysce Biosciences

Ensysce Biosciences, Inc. is a clinical-stage biotechnology company focused on developing prescription medicines designed to address opioid abuse, misuse and overdose. The company’s technology is intended to preserve the therapeutic benefits of opioid pain medicines while incorporating mechanisms that may reduce the risks associated with tampering or excessive dosing. Ensysce’s lead product candidate, PF614, is an investigational extended-release oxycodone prodrug designed to be activated in the gastrointestinal tract.

About Iterum Therapeutics

Iterum Therapeutics plc (NASDAQ:ITRM) is an Ireland-based pharmaceutical company focused on developing and commercializing anti-infective therapies for infections caused by drug-resistant bacteria. The company’s lead product is sulopenem, a penem-class antibiotic designed to provide activity against a broad range of pathogens. In 2024, the U.S. Food and Drug Administration approved Orlynvah, an oral combination of sulopenem etzadroxil and probenecid, for the treatment of uncomplicated urinary tract infections in adult women when alternative oral antibacterial treatments are not suitable.